4//SEC Filing
Ratliff John D 4
Accession 0001127602-19-014865
CIK 0000920148other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 12:01 PM ET
Size
10.0 KB
Accession
0001127602-19-014865
Insider Transaction Report
Form 4
Ratliff John D
CEO, Covance Drug Development
Transactions
- Exercise/Conversion
Common Stock
2019-04-03+2,424→ 18,025 total - Tax Payment
Common Stock
2019-04-03$156.68/sh−1,084$169,841→ 16,941 total - Exercise/Conversion
Restricted Stock Unit
2019-04-03−2,424→ 19,787 total→ Common Stock (2,424 underlying)
Holdings
- 40(indirect: By Trust)
Common Stock
- 80(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- [F2]Stock withholding to satisfy tax withholding obligations.
- [F3]The Restricted Stock Units vest in three installments as follows: 20% of the Restricted Stock Units vested on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021.
- [F4]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
Documents
Issuer
LABORATORY CORP OF AMERICA HOLDINGS
CIK 0000920148
Entity typeother
Related Parties
1- filerCIK 0001575951
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 12:01 PM ET
- Size
- 10.0 KB